The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
Incretin-based therapy is now a prevalent treatment option for patients with type 2 diabetes mellitus (T2DM). It has been associated with considerably good results in the management of hyperglycemia with cardiac or nephron-benefits. For this reason, it is recommended for individuals with cardiovascu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2020/4727390 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568605844176896 |
|---|---|
| author | Thiquynhnga Nguyen Min Gong Song Wen Xinlu Yuan Chaoxun Wang Jianlan Jin Ligang Zhou |
| author_facet | Thiquynhnga Nguyen Min Gong Song Wen Xinlu Yuan Chaoxun Wang Jianlan Jin Ligang Zhou |
| author_sort | Thiquynhnga Nguyen |
| collection | DOAJ |
| description | Incretin-based therapy is now a prevalent treatment option for patients with type 2 diabetes mellitus (T2DM). It has been associated with considerably good results in the management of hyperglycemia with cardiac or nephron-benefits. For this reason, it is recommended for individuals with cardiovascular diseases in many clinical guidelines. As an incretin hormone, glucagon-like peptide-1 (GLP-1) possesses multiple metabolic benefits such as optimizing energy usage, maintaining body weight, β cell preservation, and suppressing neurodegeneration. However, recent studies indicate that oral antidiabetic medications interact with endogenous or exogenous GLP-1. Since these drugs are transported to distal intestine portions, there are concerns whether these oral drugs directly stimulate intestinal L cells which release GLP-1, or whether they do so via indirect inhibition of the activity of dipeptidyl peptidase-IV (DPP-IV). In this review, we discuss the metabolic relationships between oral antihyperglycemic drugs from the aspect of gut, microbiota, hormones, β cell function, central nervous system, and other cellular mechanisms. |
| format | Article |
| id | doaj-art-e45f2cbdbd444268bc7ddb08505d092e |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-e45f2cbdbd444268bc7ddb08505d092e2025-02-03T00:58:42ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/47273904727390The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes MellitusThiquynhnga Nguyen0Min Gong1Song Wen2Xinlu Yuan3Chaoxun Wang4Jianlan Jin5Ligang Zhou6Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaDepartment of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, ChinaIncretin-based therapy is now a prevalent treatment option for patients with type 2 diabetes mellitus (T2DM). It has been associated with considerably good results in the management of hyperglycemia with cardiac or nephron-benefits. For this reason, it is recommended for individuals with cardiovascular diseases in many clinical guidelines. As an incretin hormone, glucagon-like peptide-1 (GLP-1) possesses multiple metabolic benefits such as optimizing energy usage, maintaining body weight, β cell preservation, and suppressing neurodegeneration. However, recent studies indicate that oral antidiabetic medications interact with endogenous or exogenous GLP-1. Since these drugs are transported to distal intestine portions, there are concerns whether these oral drugs directly stimulate intestinal L cells which release GLP-1, or whether they do so via indirect inhibition of the activity of dipeptidyl peptidase-IV (DPP-IV). In this review, we discuss the metabolic relationships between oral antihyperglycemic drugs from the aspect of gut, microbiota, hormones, β cell function, central nervous system, and other cellular mechanisms.http://dx.doi.org/10.1155/2020/4727390 |
| spellingShingle | Thiquynhnga Nguyen Min Gong Song Wen Xinlu Yuan Chaoxun Wang Jianlan Jin Ligang Zhou The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus Journal of Diabetes Research |
| title | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| title_full | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| title_fullStr | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| title_full_unstemmed | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| title_short | The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus |
| title_sort | mechanism of metabolic influences on the endogenous glp 1 by oral antidiabetic medications in type 2 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2020/4727390 |
| work_keys_str_mv | AT thiquynhnganguyen themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT mingong themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT songwen themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT xinluyuan themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT chaoxunwang themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT jianlanjin themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT ligangzhou themechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT thiquynhnganguyen mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT mingong mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT songwen mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT xinluyuan mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT chaoxunwang mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT jianlanjin mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus AT ligangzhou mechanismofmetabolicinfluencesontheendogenousglp1byoralantidiabeticmedicationsintype2diabetesmellitus |